Acalabrutinib monotherapy (continuous, until progression or intolerance)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ACALABRUTINIB`

ID	`REG-ACALABRUTINIB-CONTINUOUS`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Notes

Preferred BTKi for CLL 1L per NCCN 2025 (over ibrutinib due to less cardiac toxicity). ELEVATE-TN (1L CLL): superior PFS vs Clb+O at 5y; ELEVATE-RR (r/r): non-inferior to ibrutinib with better safety. Funding pathway must be confirmed pre-start in Ukraine.

Used By

Indication

IND-CLL-1L-BTKI - IND-CLL-1L-BTKI

Monitoring

MON-CLL-BTKI - MON-CLL-BTKI

Regimen

REG-ZANUBRUTINIB-CONTINUOUS - Zanubrutinib monotherapy (continuous, ALPINE-style)